The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In a phase 3 clinical trial, the combination showed significant improvements in progression-free survival and overall survival compared with the standard of care.
In five years, we hope to have a national system for prescreening to determine eligibility for experimental cancer medicine, allowing the UK to give patients access to trials faster than anywhere else in the world.
Results from the phase 3 VERIFY study supported the filing, showing that the drug improved hematocrit levels and lowered the frequency of required blood removals.
While we cannot ignore the wider challenges facing the NHS, the SOHO UK programme highlights the extraordinary pace of progress in haematology. Alongside sessions showcasing emerging science, others are firmly grounded in the realities of everyday clinical practice, including the management of disease in young, pregnant, and elderly patients, Dr. Tom Coats writes.
The DIDACT Foundation was established with the mission to expand structured training and mentoring opportunities in clinical trial delivery for trainee UK haematologists.
To access the SOHO Career Center click the following link.
